HIV Detail Information

Elvitegravir (ID: DG00246) Resistance Data of HIV
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20K+p.V31I+p.L45I+p.L101I+p.I135IV+p.N155H+p.E157Q+p.K160Q+p.V201I+p.K215N+p.A265V
Missense mutation 29.6 Low-level resistance [1]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 RT-PCR; Sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Five mutations (A49P, L68FL, T97A, E138k and L234V) were implicated in emergent dolutegravir resistance, with a concomitant severe compromise in viral replicative capacity.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.V151I+p.L234V+p.R263K
Missense mutation 25 Low-level resistance [2]
p.K14R+p.D25E+p.V31I+p.L45S+p.I72V+p.E96D+p.F100Y+p.L101I+p.T112V+p.T124A+p.T125A+p.K136Q+p.V201I+p.K219N+p.N222K+p.L234I+p.R263K+p.A265V+p.R269K+p.D278A
Missense mutation 50 Intermediate resistance [2]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Our results show that the R263k substitution decreased HIV-1 subtype C susceptibility to DTG and EVG by 3.3 and 50-fold, respectively. In subtype B, R263k conferred a somewhat lesser degree of drug resistance, that is, 2.1 and 25-fold decreases in susceptibility to DTG and EVG, respectively. R263k did not confer resistance against RAL in HIV-1 subtype C in accordance with results for subtype B.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.G140S+p.Q148H+p.V151I+p.L234V
Missense mutation 100 High-level resistance [3]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E11D+p.S17N+p.V31I+p.L63I+p.L68LV+p.L74I+p.E92EQ+p.E96D+p.L101I+p.T112V+p.T124N+p.T125A+p.G134N+p.K136T+p.G140GA+p.Q148QR+p.E157Q+p.K160N+p.V201I+p.T206S+p.T210TI+p.K211R+p.L234I+p.R269K+p.S283G+p.D288N
Missense mutation 100 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E11D, S17N, V31I, L63I, L68LV, L74I, E92EQ, E96D, L101I, T112V, T124N, T125A, G134N, K136T, G140GA, Q148QR, E157Q, K160N, V201I, T206S, T210TI, K211R, L234I, R269K, S283G, D288N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E11D+p.S17N+p.V31I+p.L63I+p.L74I+p.E92EQ+p.E96D+p.L101I+p.T112V+p.T124N+p.T125A+p.G134N+p.K136T+p.E157Q+p.K160N+p.V201I+p.T206S+p.T210TI+p.K211R+p.L234I+p.R269K+p.S283G+p.D288N
Missense mutation 100 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E11D, S17N, V31I, L63I, L74I, E92EQ, E96D, L101I, T112V, T124N, T125A, G134N, K136T, E157Q, K160N, V201I, T206S, T210TI, K211R, L234I, R269K, S283G, D288N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72IV+p.L101I+p.S119P+p.T122I+p.T124N+p.T125S+p.Q148R+p.V165VI+p.T218S
Missense mutation 22 Low-level resistance [5]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72IV, L101I, S119P, T122I, T124N, T125S, Q148R, V165VI, T218S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.V31I+p.M50T+p.L101I+p.S119R+p.K136Q+p.N155H+p.G163Q+p.K211R+p.I217IV+p.S283G
Missense mutation 100 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, V31I, M50T, L101I, S119R, K136Q, N155H, G163Q, K211R, I217IV, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.V31VMI+p.L45LR+p.E92EQ+p.L101I+p.T112TI+p.T124TA+p.N155H+p.S230SR
Missense mutation 85 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, V31VMI, L45LR, E92EQ, L101I, T112TI, T124TA, N155H, S230SR.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.A21T+p.L101I+p.T112V+p.I113L+p.N155H
Missense mutation 36 Intermediate resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, A21T, L101I, T112V, I113L, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.A21T+p.M50I+p.E92G+p.S119P+p.T124A+p.K188KR+p.I208IM+p.D256E
Missense mutation 20 Low-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, A21T, M50I, E92G, S119P, T124A, K188KR, I208IM, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.A23V+p.L28I+p.V37I+p.D41DN+p.G70GR+p.T97TA+p.L101I+p.P142PT+p.V151VI+p.N155NH+p.E157EQ+p.V201VI+p.T206S+p.K215N+p.D232DE+p.D256E+p.S283G
Missense mutation 22 Low-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, A23V, L28I, V37I, D41DN, G70GR, T97TA, L101I, P142PT, V151VI, N155NH, E157EQ, V201VI, T206S, K215N, D232DE, D256E, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.A23V+p.L28I+p.V37I+p.D41DN+p.T97TA+p.L101I+p.T112TA+p.S119SR+p.V151VI+p.N155H+p.E157EQ+p.V201I+p.T206S+p.K215N+p.D232DE+p.D256E+p.S283G
Missense mutation 73 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, A23V, L28I, V37I, D41DN, T97TA, L101I, T112TA, S119SR, V151VI, N155H, E157EQ, V201I, T206S, K215N, D232DE, D256E, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.K14R+p.A21T+p.A23V+p.E92EQ+p.L101I+p.S119T+p.Q148QR+p.N155NH
Missense mutation 50 Intermediate resistance [6]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, K14R, A21T, A23V, E92EQ, L101I, S119T, Q148QR, N155NH.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.K14R+p.S17T+p.S39C+p.H51HY+p.I60V+p.L68V+p.E92Q+p.T112I+p.T124A+p.T206S+p.E212A
Missense mutation 100 High-level resistance [6]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, K14R, S17T, S39C, H51HY, I60V, L68V, E92Q, T112I, T124A, T206S, E212A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.M50I+p.S119P+p.T122I+p.N155H+p.S195T+p.V201I+p.T218I
Missense mutation 59 Intermediate resistance [6]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, M50I, S119P, T122I, N155H, S195T, V201I, T218I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S17T+p.A23V+p.I73V+p.E92Q+p.T124A+p.S153A+p.G189GR+p.G193E+p.V201I+p.I208M+p.E212Y+p.Q216H+p.I220L
Missense mutation 100 High-level resistance [6]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S17T, A23V, I73V, E92Q, T124A, S153A, G189GR, G193E, V201I, I208M, E212Y, Q216H, I220L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.K34R+p.I72IV+p.I84M+p.A91T+p.L101I+p.T125V+p.G140S+p.Q148H+p.I161T+p.V201I+p.K211KR+p.S230N+p.V260L+p.P261F+p.S283G
Missense mutation 100 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, K34R, I72IV, I84M, A91T, L101I, T125V, G140S, Q148H, I161T, V201I, K211KR, S230N, V260L, P261F, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24SN+p.D25E+p.L101I+p.S119P+p.T122I+p.K136N+p.N155H+p.D279DN
Missense mutation 36 Intermediate resistance [5]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24SN, D25E, L101I, S119P, T122I, K136N, N155H, D279DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q+p.L101I+p.T112V+p.T210TI+p.I220V+p.L242LF+p.D253E+p.R284G
Missense mutation 27 Low-level resistance [6]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, L101I, T112V, T210TI, I220V, L242LF, D253E, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K111KT+p.G140S+p.Q148H+p.N254K+p.A265AV+p.S283G
Missense mutation 100 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K111KT, G140S, Q148H, N254K, A265AV, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.R20K+p.S24N+p.D25E+p.V31I+p.G59E+p.I60V+p.E92Q+p.L101I+p.T124A+p.T125A+p.D167DE+p.K215R+p.N222K
Missense mutation 36 Intermediate resistance [6]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, R20K, S24N, D25E, V31I, G59E, I60V, E92Q, L101I, T124A, T125A, D167DE, K215R, N222K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S17N+p.K34R+p.G59E+p.S119P+p.T124N+p.T125A+p.G140C+p.Q148R+p.H183HP+p.V201I+p.S230N+p.D256E
Missense mutation 100 High-level resistance [5]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, S17N, K34R, G59E, S119P, T124N, T125A, G140C, Q148R, H183HP, V201I, S230N, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S17N+p.V31VI+p.I60M+p.L101I+p.T112V+p.T124A+p.I135V+p.E138D+p.G140S+p.Q148H+p.K188KR+p.V201I+p.R263RK+p.A265V+p.S283G+p.R284G+p.D286N
Missense mutation 100 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, S17N, V31VI, I60M, L101I, T112V, T124A, I135V, E138D, G140S, Q148H, K188KR, V201I, R263RK, A265V, S283G, R284G, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S24N+p.C65CG+p.T66TI+p.E92EQ+p.L101V+p.K111R+p.T112V+p.T124A+p.V126M+p.N155NH+p.E157EQ+p.K160Q+p.D167E+p.V201I+p.K211R+p.S230N
Missense mutation 19.7 Low-level resistance [5]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, S24N, C65CG, T66TI, E92EQ, L101V, K111R, T112V, T124A, V126M, N155NH, E157EQ, K160Q, D167E, V201I, K211R, S230N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.V31I+p.T124X+p.T125TA+p.N155H+p.K215N+p.S230N+p.R231K+p.D253E+p.N254Q+p.S255G+p.D256E+p.K258N+p.V259L+p.V260L
Missense mutation 15 Low-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, V31I, T124X, T125TA, N155H, K215N, S230N, R231K, D253E, N254Q, S255G, D256E, K258N, V259L, V260L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L101I+p.N155H+p.K156N+p.I208L
Missense mutation 59 Intermediate resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L101I, N155H, K156N, I208L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I+p.E92Q+p.T125A+p.I135V+p.M154I+p.I162V+p.V201I+p.K215N+p.L234I
Missense mutation 44 Intermediate resistance [6]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50I, E92Q, T125A, I135V, M154I, I162V, V201I, K215N, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.A49P+p.L101LF+p.T124A+p.S153SF+p.N155H+p.E170EA+p.H171HR+p.L172LF+p.G193E+p.V201I+p.T218S+p.I220LF+p.D232DN+p.L241LF+p.L242LF+p.D253E+p.S255R
Missense mutation 58 Intermediate resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, A49P, L101LF, T124A, S153SF, N155H, E170EA, H171HR, L172LF, G193E, V201I, T218S, I220LF, D232DN, L241LF, L242LF, D253E, S255R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.D25E+p.F26FL+p.M50I+p.L101I+p.S119SR+p.T124A+p.N155H+p.K156N+p.Q221S+p.N222K
Missense mutation 98 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, D25E, F26FL, M50I, L101I, S119SR, T124A, N155H, K156N, Q221S, N222K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.I84L+p.V88VL+p.E92Q+p.T124S+p.K156N+p.I203M+p.D256E
Missense mutation 42 Intermediate resistance [5]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I84L, V88VL, E92Q, T124S, K156N, I203M, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.K34R+p.K46KR+p.M50L+p.E92Q+p.T124A+p.T125A+p.V201I+p.A205S+p.T206S+p.I208L+p.K211RG+p.E212A
Missense mutation 34 Intermediate resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, K34R, K46KR, M50L, E92Q, T124A, T125A, V201I, A205S, T206S, I208L, K211RG, E212A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.M50I+p.E92EQ+p.E96EA+p.T124A+p.N155NH+p.G163E+p.V201I+p.D256DE
Missense mutation 47 Intermediate resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, M50I, E92EQ, E96EA, T124A, N155NH, G163E, V201I, D256DE.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.R20RK+p.V31I+p.M50I+p.T66TI+p.E92EQ+p.T124A+p.N155NH+p.K156N+p.V165I+p.F181FL+p.V201I+p.S255K+p.I268L
Missense mutation 28 Low-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, R20RK, V31I, M50I, T66TI, E92EQ, T124A, N155NH, K156N, V165I, F181FL, V201I, S255K, I268L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31I+p.L101I+p.T122TI+p.T124S+p.T125A+p.I135IV+p.Y143X+p.N155NH+p.E198D+p.V201I+p.T206S+p.D232E+p.A265V
Missense mutation 12 Potential low-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, L101I, T122TI, T124S, T125A, I135IV, Y143X, N155NH, E198D, V201I, T206S, D232E, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17SN+p.R20RK+p.N27G+p.L28I+p.L45Q+p.I72IV+p.P90PL+p.G140S+p.Q148H+p.Q216QH+p.D256DE+p.D279DG
Missense mutation 100 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17SN, R20RK, N27G, L28I, L45Q, I72IV, P90PL, G140S, Q148H, Q216QH, D256DE, D279DG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S24G+p.D25E+p.L28I+p.E35Q+p.L45V+p.T125A+p.G140S+p.Q148H+p.V201I+p.S230N+p.S283R+p.R284G
Missense mutation 89 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24G, D25E, L28I, E35Q, L45V, T125A, G140S, Q148H, V201I, S230N, S283R, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S39C+p.Y99H+p.N155H+p.I162IV+p.G163GR+p.V201I+p.D232DN
Missense mutation 67 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S39C, Y99H, N155H, I162IV, G163GR, V201I, D232DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66TA+p.L101LI+p.M154L+p.N155NH+p.V201I+p.D232DN
Missense mutation 16 Low-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66TA, L101LI, M154L, N155NH, V201I, D232DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.I84M+p.E92Q+p.L101I+p.K111T+p.I135V+p.V201I+p.T206S+p.K211R+p.E212T+p.K219N
Missense mutation 30 Intermediate resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, I84M, E92Q, L101I, K111T, I135V, V201I, T206S, K211R, E212T, K219N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.K111T+p.S119G+p.T122I+p.T125A+p.G140S+p.Q148H+p.Q164QP+p.Q168QP+p.H171HP+p.R231K+p.D288N
Missense mutation 100 High-level resistance [4]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, K111T, S119G, T122I, T125A, G140S, Q148H, Q164QP, Q168QP, H171HP, R231K, D288N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66A+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 11 Potential low-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E338Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.E157Q+p.D232N
Missense mutation 11 Potential low-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E339Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 15 Low-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E340Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146L+p.D232N
Missense mutation 15 Low-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E341Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.F121Y
Missense mutation 16 Low-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E342Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92G+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 16 Low-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E343Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.V151L+p.D232N
Missense mutation 20 Low-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E344Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 20 Low-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E345Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 20 Low-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E346Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.P145S+p.D232N
Missense mutation 28 Low-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E347Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
Missense mutation 31 Intermediate resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E349Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 35 Intermediate resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E350Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
Missense mutation 40 Intermediate resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E351Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 40 Intermediate resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E352Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 43 Intermediate resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E353Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 44 Intermediate resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E354Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66K+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 50 Intermediate resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E355Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.E157Q+p.D232N
Missense mutation 66 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E356Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S119P+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 76 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E357Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148K+p.D232N
Missense mutation 100 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E358Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
Missense mutation 100 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E359Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146I+p.D232N
Missense mutation 100 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E360Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
Missense mutation 100 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E361Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
Missense mutation 100 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E362Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.E157Q+p.D232N
Missense mutation 100 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E363Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148R+p.D232N
Missense mutation 100 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E364Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148H+p.D232N
Missense mutation 100 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E365Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148K+p.D232N
Missense mutation 100 High-level resistance [7]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E366Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.H51Y+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 100 High-level resistance [8]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, H51Y, I72V, E92Q, S123G, T124A, K127R, S147G, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.H51Y+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.S147G+p.E157Q+p.D232N
Missense mutation 100 High-level resistance [8]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, H51Y, I72V, E92Q, S123G, T124A, K127R, S147G, E157Q, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 40 Intermediate resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72V, E92Q, S123G, T124A, K127R, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 100 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72V, E92Q, S123G, T124A, K127R, N155H, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 76 High-level resistance [8]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72V, E92Q, S123G, T124A, K127R, S147G, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.F121Y+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 10.7 Potential low-level resistance [8]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72V, F121Y, S123G, T124A, K127R, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138K+p.S147G+p.Q148R+p.D232N
Missense mutation 100 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72V, S123G, T124A, K127R, E138K, S147G, Q148R, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.N155H+p.D232N
Missense mutation 100 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72V, S123G, T124A, K127R, Q148R, N155H, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.L68I+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 43 Intermediate resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, L68I, I72V, E92Q, S123G, T124A, K127R, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.L68V+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 67 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, L68V, I72V, E92Q, S123G, T124A, K127R, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.L68V+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 51 Intermediate resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, L68V, I72V, S123G, T124A, K127R, N155H, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.L68V+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
Missense mutation 100 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, L68V, I72V, S123G, T124A, K127R, Q148R, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.F121Y+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 33.7 Intermediate resistance [8]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, T66I, I72V, F121Y, S123G, T124A, K127R, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N+p.R263K
Missense mutation 93.8 High-level resistance [8]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, T66I, I72V, S123G, T124A, K127R, D232N, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.S153Y+p.D232N
Missense mutation 37.4 Intermediate resistance [8]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, T66I, I72V, S123G, T124A, K127R, S153Y, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K+p.G140A+p.Q148R
Missense mutation 100 High-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, G140A, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K+p.Q148K
Missense mutation 100 High-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K+p.Q148R
Missense mutation 100 High-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q+p.G140A
Missense mutation 54 Intermediate resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, G140A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q+p.N155H
Missense mutation 94 High-level resistance [11]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q+p.Q148R
Missense mutation 94 High-level resistance [11]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q
Missense mutation 26 Low-level resistance [11]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140A+p.Q148R
Missense mutation 100 High-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140A, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.H51Y+p.I72V+p.I113V+p.L234V+p.R263K
Missense mutation 42 Intermediate resistance [12]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included H51Y, I72V, I113V, L234V, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72A+p.N155H
Missense mutation 36 Intermediate resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72A, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.E92Q+p.I113V+p.L234V
Missense mutation 33 Intermediate resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, E92Q, I113V, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.E92Q+p.I113V+p.N155H+p.L234V
Missense mutation 100 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, E92Q, I113V, N155H, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.E138K+p.S147G+p.Q148R+p.L234V
Missense mutation 100 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, E138K, S147G, Q148R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.G140S+p.Q148H+p.L234V
Missense mutation 100 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, G140S, Q148H, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.N155H+p.L234V
Missense mutation 38 Intermediate resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, N155H, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Q148K+p.L234V
Missense mutation 67 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Q148K, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Q148R+p.L234V
Missense mutation 100 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Q148R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143A+p.S230R+p.L234V
Missense mutation 66 High-level resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143A, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143C+p.S230R+p.L234V
Missense mutation 35 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143C, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143G+p.S230R+p.L234V
Missense mutation 55 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143G, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143R+p.L234V
Missense mutation 29 Low-level resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143R+p.S230R+p.L234V
Missense mutation 34 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143R, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143S+p.S230R+p.L234V
Missense mutation 49 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143S, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143A+p.S230R+p.L234V
Missense mutation 61 High-level resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143A, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143C+p.S230R+p.L234V
Missense mutation 33 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143C, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143G+p.S230R+p.L234V
Missense mutation 55 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143G, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143R+p.L234V
Missense mutation 25 Low-level resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143R+p.S230R+p.L234V
Missense mutation 45 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143R, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143S+p.S230R+p.L234V
Missense mutation 50 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143S, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143A+p.G163R+p.L234V
Missense mutation 18 Low-level resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143A, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143A+p.S230R+p.L234V
Missense mutation 53 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143A, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143C+p.S230R+p.L234V
Missense mutation 25 Low-level resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143C, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143G+p.S230R+p.L234V
Missense mutation 49 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143G, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143R+p.G163R+p.L234V
Missense mutation 34 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143R, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143R+p.S230R+p.L234V
Missense mutation 39 Intermediate resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143R, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143S+p.S230R+p.L234V
Missense mutation 26 Low-level resistance [13]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143S, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L45Q+p.T115H
Missense mutation 23 Low-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L45Q, T115H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119P
Missense mutation 17 Low-level resistance [14]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119R
Missense mutation 26 Low-level resistance [14]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N155H
Missense mutation 30 Intermediate resistance [11]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.P145S
Missense mutation 28 Low-level resistance [15]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included P145S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q146I
Missense mutation 100 High-level resistance [15]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q146L
Missense mutation 15 Low-level resistance [15]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148K
Missense mutation 94 High-level resistance [15]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148R+p.N155H
Missense mutation 100 High-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148R
Missense mutation 92 High-level resistance [15]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119R+p.F121Y
Missense mutation 74 High-level resistance [14]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S119R, F121Y.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S24G+p.N155H+p.D253E
Missense mutation 17 Low-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24G, N155H, D253E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.E138K+p.Q148K
Missense mutation 100 High-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E138K, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.E138K+p.Q148R
Missense mutation 100 High-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.E92Q
Missense mutation 94 High-level resistance [11]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.I72V+p.E92Q+p.I113V+p.L234V
Missense mutation 100 High-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, I72V, E92Q, I113V, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.I72V+p.I113V+p.L234V
Missense mutation 15 Low-level resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, I72V, I113V, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.I72V+p.I113V+p.S147G+p.L234V
Missense mutation 46 Intermediate resistance [9]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, I72V, I113V, S147G, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.N155H
Missense mutation 94 High-level resistance [11]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.Q148K
Missense mutation 100 High-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.Q148R
Missense mutation 94 High-level resistance [11]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.R263K
Missense mutation 84 High-level resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.S153F
Missense mutation 30 Intermediate resistance [10]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, S153F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66K
Missense mutation 40 Intermediate resistance [11]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119R
Missense mutation 13 Potential low-level resistance [14]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V151L
Missense mutation 20 Low-level resistance [15]
Resistant Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V151L.
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.G118R+p.E138K+p.V151I+p.L234V
Missense mutation 4.8 Susceptible [16]
p.I72V+p.I113V+p.E138K+p.V151I+p.L234V
Missense mutation 0.8 Susceptible [16]
p.I72V+p.I113V+p.G118R+p.V151I+p.L234V
Missense mutation 5.5 Susceptible [16]
p.H51Y+p.I72V+p.I113V+p.V151I+p.L234V
Missense mutation 2 Susceptible [16]
p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.L74I+p.A91E+p.L101I+p.T112V+p.G118R+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.E138K+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D
Missense mutation 5.2 Susceptible [16]
p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.L74I+p.A91E+p.L101I+p.T112V+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.E138K+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D
Missense mutation 1 Susceptible [16]
p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.L74I+p.A91E+p.L101I+p.T112V+p.G118R+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D
Missense mutation 7.7 Susceptible [16]
p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.H51Y+p.L74I+p.A91E+p.L101I+p.T112V+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D
Missense mutation 2.1 Susceptible [16]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
In Vitro Model BL21 cells Cerebrospinal fluid Homo sapiens (Human) CVCL_M639
Experiment for
Molecule Alteration		 Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to elvitegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20K+p.V31I+p.L45I+p.L101I+p.K111KR+p.I135IV+p.E157Q+p.K160Q+p.V201I+p.K215N+p.A265AV
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 RT-PCR; Sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Five mutations (A49P, L68FL, T97A, E138k and L234V) were implicated in emergent dolutegravir resistance, with a concomitant severe compromise in viral replicative capacity.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V32I+p.I36V+p.D41G+p.M50L+p.I72V+p.L101I+p.T124N+p.T125A+p.I135V+p.V201I+p.I208L+p.D256E
Missense mutation 1.3 Susceptible [3]
p.S17N+p.V32I+p.I36V+p.D41G+p.M50L+p.I72V+p.L101I+p.T124N+p.T125A+p.I135V+p.Q148N+p.V201I+p.I208L+p.D256E
Missense mutation 4.5 Susceptible [3]
p.S17N+p.V32I+p.I36V+p.D41G+p.M50L+p.I72V+p.L101I+p.T124N+p.T125A+p.I135V+p.G140S+p.Q148N+p.V201I+p.I208L+p.D256E
Missense mutation 4.2 Susceptible [3]
p.I72V+p.I113V+p.Q148H+p.V151I+p.L234V
Missense mutation 5.5 Susceptible [3]
p.I72V+p.I113V+p.G140S+p.Q148N+p.V151I+p.L234V
Missense mutation 3.1 Susceptible [3]
p.I72V+p.I113V+p.Q148N+p.V151I+p.L234V
Missense mutation 2.4 Susceptible [3]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A21T+p.L45V+p.T124Q+p.T125V+p.I182V+p.D256E+p.R262L
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A21T, L45V, T124Q, T125V, I182V, D256E, R262L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A23AV+p.L101LF+p.K156N+p.R187RK+p.K188R+p.V201I+p.S230SN+p.D256E
Missense mutation 1.2 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A23AV, L101LF, K156N, R187RK, K188R, V201I, S230SN, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A23V+p.S39C+p.L101I+p.T124N+p.T125A+p.I135V+p.D167E+p.F181L+p.V201I+p.K215N+p.D270N
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A23V, S39C, L101I, T124N, T125A, I135V, D167E, F181L, V201I, K215N, D270N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A8AG+p.E11D+p.S24G+p.D25E+p.L28I+p.V37VI+p.S39C+p.K71KR+p.L101I+p.K215N+p.S230N
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A8AG, E11D, S24G, D25E, L28I, V37VI, S39C, K71KR, L101I, K215N, S230N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A8AV+p.E10D+p.S24A+p.L101I+p.K111T+p.S119T+p.T124X+p.T125A+p.K160R+p.K188R+p.G193E+p.D279G+p.D286N
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A8AV, E10D, S24A, L101I, K111T, S119T, T124X, T125A, K160R, K188R, G193E, D279G, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.C56CS+p.I72IV+p.K111KT+p.I113IVM+p.I208IL+p.K211KR+p.N254K+p.A265V+p.S283G
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included C56CS, I72IV, K111KT, I113IVM, I208IL, K211KR, N254K, A265V, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D25DE+p.V31VI+p.L74I+p.G163E+p.H171Q
Missense mutation 2.5 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D25DE, V31VI, L74I, G163E, H171Q.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D25E+p.P90PS+p.T124TA+p.V201I+p.S230N
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D25E, P90PS, T124TA, V201I, S230N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6DE+p.K14R+p.S24N+p.L74I+p.T112IV+p.T124N+p.T125A+p.G134N+p.K136T+p.V201I+p.T206S+p.L234I+p.S255N+p.D256E+p.S283G+p.R284G+p.D286N
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6DE, K14R, S24N, L74I, T112IV, T124N, T125A, G134N, K136T, V201I, T206S, L234I, S255N, D256E, S283G, R284G, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6DE+p.S17N+p.L45V+p.K111KR+p.T112I+p.T124N+p.T125A+p.I203IM+p.T206S+p.D256E
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6DE, S17N, L45V, K111KR, T112I, T124N, T125A, I203IM, T206S, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6DN+p.K14KR+p.S17N+p.S24D+p.D25E+p.L28LI+p.S39C+p.S57SG+p.T66TI+p.E92EQ+p.L101I+p.T124N+p.V165I+p.D286N
Missense mutation 5.6 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6DN, K14KR, S17N, S24D, D25E, L28LI, S39C, S57SG, T66TI, E92EQ, L101I, T124N, V165I, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.D25E+p.L101I+p.V110T+p.T112V+p.K156N+p.E157Q+p.K215N+p.D232E+p.L234H+p.D253E+p.D256E+p.D270N
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, D25E, L101I, V110T, T112V, K156N, E157Q, K215N, D232E, L234H, D253E, D256E, D270N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E10D+p.E11D+p.K14R+p.V31I+p.M50T+p.I60L+p.K111Q+p.T124A+p.T206S
Missense mutation 1.5 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, E11D, K14R, V31I, M50T, I60L, K111Q, T124A, T206S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E10D+p.E13ED+p.S17SN+p.V31VI+p.S57SN+p.G106A+p.T112TI+p.S119P+p.T122I+p.T124N+p.V201I+p.T206S+p.I208L+p.K211R+p.D256E
Missense mutation 1.3 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, E13ED, S17SN, V31VI, S57SN, G106A, T112TI, S119P, T122I, T124N, V201I, T206S, I208L, K211R, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E10D+p.I72IV+p.A91S+p.S119G+p.T122I+p.T124A+p.T125A+p.I220L+p.Y227F+p.L234I
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, I72IV, A91S, S119G, T122I, T124A, T125A, I220L, Y227F, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E10D+p.L45V+p.L101I+p.S119P+p.T122I+p.T124A
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, L45V, L101I, S119P, T122I, T124A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E10D+p.M22MI+p.A23AV+p.T124N+p.V201I+p.D232E+p.D253DE+p.D256E
Missense mutation 1.4 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, M22MI, A23AV, T124N, V201I, D232E, D253DE, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E10D+p.S17N+p.A23V+p.E35Q+p.S39N+p.L45V+p.M50I+p.T124TN+p.V151VI+p.V201I+p.K264KR+p.E287EK
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, S17N, A23V, E35Q, S39N, L45V, M50I, T124TN, V151VI, V201I, K264KR, E287EK.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E11D+p.S17N+p.V31I+p.L63I+p.L74I+p.E96D+p.L101I+p.T112V+p.T124N+p.T125A+p.G134N+p.K136T+p.E157Q+p.K160N+p.V201I+p.T206S+p.K211R+p.L234I+p.R269K+p.S283G+p.D288N
Missense mutation 2.7 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E11D, S17N, V31I, L63I, L74I, E96D, L101I, T112V, T124N, T125A, G134N, K136T, E157Q, K160N, V201I, T206S, K211R, L234I, R269K, S283G, D288N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.K14KR+p.A23AV+p.S24SG+p.P30PA+p.S39SC+p.I72IV+p.L74I+p.T124A+p.V201I+p.T206S+p.I208L+p.E212A+p.K215N+p.S283G
Missense mutation 1.5 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, K14KR, A23AV, S24SG, P30PA, S39SC, I72IV, L74I, T124A, V201I, T206S, I208L, E212A, K215N, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.K7KR+p.S17N+p.L74I+p.L101I+p.T124A+p.T125TA+p.G163D+p.F181FL+p.R187K+p.K188KR+p.K211T+p.E212A+p.Q221S
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, K7KR, S17N, L74I, L101I, T124A, T125TA, G163D, F181FL, R187K, K188KR, K211T, E212A, Q221S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.P30S+p.S39C+p.K111KR+p.V201I+p.T206S+p.S230H+p.D253DE+p.S283SG
Missense mutation 1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, P30S, S39C, K111KR, V201I, T206S, S230H, D253DE, S283SG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.S17N+p.A98G+p.L101I+p.T124N+p.K136N+p.F181L+p.V201I+p.A265V
Missense mutation 1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, S17N, A98G, L101I, T124N, K136N, F181L, V201I, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.S17N+p.E35Q+p.S39N+p.D55S+p.I72IV+p.L101I+p.T124A+p.F181L+p.V201I+p.I220L+p.R284G
Missense mutation 1.7 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, S17N, E35Q, S39N, D55S, I72IV, L101I, T124A, F181L, V201I, I220L, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.S17N+p.V31I+p.T112IV+p.T124N+p.T125V+p.L158F+p.H171HQ+p.D232E+p.A265V
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, S17N, V31I, T112IV, T124N, T125V, L158F, H171HQ, D232E, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10A+p.E11D+p.S17N+p.V32I+p.K42R+p.I84L+p.L101I+p.S119P+p.T124A+p.T125A+p.I135V+p.K136Q+p.V165I+p.V201I+p.T218I+p.D256E+p.S283G
Missense mutation 1.2 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10A, E11D, S17N, V32I, K42R, I84L, L101I, S119P, T124A, T125A, I135V, K136Q, V165I, V201I, T218I, D256E, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.E11D+p.D25DE+p.F26FY+p.S39C+p.L45Q+p.L101I+p.T124A+p.I135V+p.T174TI+p.Q216H+p.R231RG
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, E11D, D25DE, F26FY, S39C, L45Q, L101I, T124A, I135V, T174TI, Q216H, R231RG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.E11D+p.E35EK+p.I72IV+p.L101LI+p.T124TA+p.G193D+p.S195C+p.V201VI+p.T206S+p.I208L+p.E212A+p.N254Q+p.R269K+p.D286N
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, E11D, E35EK, I72IV, L101LI, T124TA, G193D, S195C, V201VI, T206S, I208L, E212A, N254Q, R269K, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.E11ED+p.V31VI+p.S39SC+p.M50I+p.I60IM+p.G106A+p.K156N+p.V201I+p.T206S+p.D232E+p.L234H
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, E11ED, V31VI, S39SC, M50I, I60IM, G106A, K156N, V201I, T206S, D232E, L234H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72IV+p.L101I+p.S119P+p.T122I+p.T124N+p.T125S+p.T218S
Missense mutation 1.9 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72IV, L101I, S119P, T122I, T124N, T125S, T218S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.K14KR+p.L101I+p.S119G+p.T122I+p.T124A+p.V201I+p.I220L
Missense mutation 1 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, K14KR, L101I, S119G, T122I, T124A, V201I, I220L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.K34R+p.I72IV+p.L101I+p.K111R+p.T112TI+p.T124N+p.T125A+p.A175T+p.V201I+p.K211R+p.S230N+p.S283G
Missense mutation 1.5 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, K34R, I72IV, L101I, K111R, T112TI, T124N, T125A, A175T, V201I, K211R, S230N, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.R20RK+p.M50I+p.L101I+p.T112I+p.S119P+p.T124A+p.T125A+p.I135L+p.T206S+p.D279DN
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, R20RK, M50I, L101I, T112I, S119P, T124A, T125A, I135L, T206S, D279DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T124A+p.T125A+p.I135IV+p.K156N+p.V201I+p.I220V
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, T124A, T125A, I135IV, K156N, V201I, I220V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T124N+p.T125A+p.I135IV+p.M154I+p.P261F+p.R262F
Missense mutation 1.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, T124N, T125A, I135IV, M154I, P261F, R262F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T93TA+p.T124TA+p.I135IV+p.V201I+p.E212EG+p.R284G
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, T93TA, T124TA, I135IV, V201I, E212EG, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.V31I+p.M50MI+p.I84IML+p.L101I+p.G106A+p.K111X+p.T112X+p.T124TA+p.T125TA+p.I135IV+p.V151I
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, V31I, M50MI, I84IML, L101I, G106A, K111X, T112X, T124TA, T125TA, I135IV, V151I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.V31I+p.M50T+p.L101I+p.K136Q+p.G163Q+p.K211R+p.S283G
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, V31I, M50T, L101I, K136Q, G163Q, K211R, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10ED+p.A23V+p.N27D+p.M50I+p.A91T+p.Q95P+p.L101I+p.T112A+p.S119R+p.T125P+p.V201I+p.T206S+p.L241LF
Missense mutation 2 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10ED, A23V, N27D, M50I, A91T, Q95P, L101I, T112A, S119R, T125P, V201I, T206S, L241LF.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10ED+p.E11ED+p.E13ED+p.M50L+p.L101I+p.K111T+p.T125A+p.A128T+p.Y227F+p.S230N+p.D256E+p.A265V
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10ED, E11ED, E13ED, M50L, L101I, K111T, T125A, A128T, Y227F, S230N, D256E, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10ED+p.E11ED+p.S24X+p.L101I+p.K111R+p.I135IV+p.V201I+p.T206S+p.K211R+p.E212I+p.T218Q+p.K219Q+p.L241LF+p.L242LF+p.S255KQ
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10ED, E11ED, S24X, L101I, K111R, I135IV, V201I, T206S, K211R, E212I, T218Q, K219Q, L241LF, L242LF, S255KQ.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.A21AT+p.A23AV+p.D25E+p.K111T+p.I113IV+p.D278DG
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, A21AT, A23AV, D25E, K111T, I113IV, D278DG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.A21AT+p.V31I+p.A91E+p.L101I+p.T112V+p.S119R+p.T122I+p.T206S+p.N254NS
Missense mutation 1.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, A21AT, V31I, A91E, L101I, T112V, S119R, T122I, T206S, N254NS.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.A21S+p.A23V+p.S24G+p.V37I+p.S39C+p.I60V+p.L101I+p.K219N+p.N222K
Missense mutation 1.3 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, A21S, A23V, S24G, V37I, S39C, I60V, L101I, K219N, N222K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.A21T+p.L101LI+p.K111Q+p.T112A+p.S119SG+p.T122TI+p.T125TA+p.A128AT
Missense mutation 1.9 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, A21T, L101LI, K111Q, T112A, S119SG, T122TI, T125TA, A128AT.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.A21T+p.V31I+p.A91X+p.L101I+p.T112X+p.S119R+p.T122IV+p.S123SC+p.T124TN+p.Q148QR+p.T206S+p.T218TS
Missense mutation 1.8 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, A21T, V31I, A91X, L101I, T112X, S119R, T122IV, S123SC, T124TN, Q148QR, T206S, T218TS.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.A23V+p.L28I+p.V37I+p.L101I+p.V201VI+p.T206S+p.K215N+p.D232DE+p.D256E+p.S283G
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, A23V, L28I, V37I, L101I, V201VI, T206S, K215N, D232DE, D256E, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.D25E+p.V31I+p.L101LI+p.K111T+p.I113IV+p.S119X+p.T122TI+p.T124TA+p.V126VMI+p.V201I+p.S230N+p.A265V
Missense mutation 0.8 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, D25E, V31I, L101LI, K111T, I113IV, S119X, T122TI, T124TA, V126VMI, V201I, S230N, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.D25E+p.V31I+p.M50I+p.M154L+p.V201I
Missense mutation 2.1 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, D25E, V31I, M50I, M154L, V201I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.E13D+p.A21T+p.L101I+p.S119G+p.T122I+p.T124S+p.K136N+p.D256E
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, E13D, A21T, L101I, S119G, T122I, T124S, K136N, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.E13D+p.A21T+p.M50MI+p.T97TA+p.L101I+p.S119G+p.T122I+p.T124S+p.K136N+p.N155NH+p.D256E
Missense mutation 3.5 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, E13D, A21T, M50MI, T97TA, L101I, S119G, T122I, T124S, K136N, N155NH, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.E13D+p.V31I+p.K71KR+p.L101I+p.S119P+p.T122I+p.T124TN+p.G163E+p.D256E
Missense mutation 1.5 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, E13D, V31I, K71KR, L101I, S119P, T122I, T124TN, G163E, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.E13ED+p.G70GE+p.L101I+p.S119R+p.T122TI+p.T124TN+p.R187RK+p.K188KR+p.G193E+p.V201I+p.S283SG
Missense mutation 1.3 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, E13ED, G70GE, L101I, S119R, T122TI, T124TN, R187RK, K188KR, G193E, V201I, S283SG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.F26Y+p.L28I+p.V37I+p.S39C+p.M50I+p.G106A+p.T112R+p.T125A+p.V126L+p.V201I+p.T206S+p.K211R+p.K219N+p.N222K+p.S255N+p.I268L+p.M275V+p.V281M+p.S283G
Missense mutation 1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, F26Y, L28I, V37I, S39C, M50I, G106A, T112R, T125A, V126L, V201I, T206S, K211R, K219N, N222K, S255N, I268L, M275V, V281M, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.H12HR+p.L74LIM+p.A86AV+p.T93TI+p.L101I+p.K111KT+p.I113IV+p.S119AG+p.T122TI+p.T124N+p.S195T+p.V201I+p.T206S+p.Y227F+p.L234I+p.S255N+p.D256E+p.S283G
Missense mutation 0.9 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, H12HR, L74LIM, A86AV, T93TI, L101I, K111KT, I113IV, S119AG, T122TI, T124N, S195T, V201I, T206S, Y227F, L234I, S255N, D256E, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.K14KR+p.S24SN+p.L28I+p.M50MIT+p.V201VI+p.I203IM+p.T218I
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, K14KR, S24SN, L28I, M50MIT, V201VI, I203IM, T218I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.K14R+p.A21AT+p.T112V+p.T125A+p.G163T+p.S230X+p.D232DE+p.L234LF
Missense mutation 1.5 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, K14R, A21AT, T112V, T125A, G163T, S230X, D232DE, L234LF.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.K14R+p.S17T+p.S39SC+p.I60V+p.T112TI+p.I113IVL+p.T124A+p.T206S+p.E212A+p.N254NS+p.S283SG+p.R284RG
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, K14R, S17T, S39SC, I60V, T112TI, I113IVL, T124A, T206S, E212A, N254NS, S283SG, R284RG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.K14R+p.S24N+p.D25E+p.M50I+p.T124A+p.T125A+p.I220L+p.I268L
Missense mutation 1.8 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, K14R, S24N, D25E, M50I, T124A, T125A, I220L, I268L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.L101I+p.F181L+p.G193E+p.V201I+p.I220L+p.Y227F+p.D256E+p.D279N
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, L101I, F181L, G193E, V201I, I220L, Y227F, D256E, D279N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.L101I+p.T124A+p.K136KT+p.F181L+p.G193R+p.V201I+p.T206S+p.D253E+p.D256E+p.R284RG
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, L101I, T124A, K136KT, F181L, G193R, V201I, T206S, D253E, D256E, R284RG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.M50I+p.S119P+p.T122I+p.S195T+p.V201I+p.T218I+p.A265V
Missense mutation 1.6 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, M50I, S119P, T122I, S195T, V201I, T218I, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.M50MI+p.V88I+p.K111T+p.T112TI+p.S119P+p.T122TI+p.T125TA+p.V201I+p.T210TI+p.L234LF+p.L242LF
Missense mutation 2.1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, M50MI, V88I, K111T, T112TI, S119P, T122TI, T125TA, V201I, T210TI, L234LF, L242LF.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.R20K+p.L101I+p.I162IV+p.S195T+p.D278DN+p.S283SG
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, R20K, L101I, I162IV, S195T, D278DN, S283SG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.R20KE+p.S39SG+p.D41N+p.G70GR+p.T112I+p.V151I+p.N155NH+p.V201I
Missense mutation 1.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, R20KE, S39SG, D41N, G70GR, T112I, V151I, N155NH, V201I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.R20RK+p.S24SN+p.K34KR+p.I72IV+p.I84IM+p.A91AT+p.L101LI+p.T112TI+p.T125X+p.V151VI+p.V201I+p.S230SN+p.S283SG
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, R20RK, S24SN, K34KR, I72IV, I84IM, A91AT, L101LI, T112TI, T125X, V151VI, V201I, S230SN, S283SG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S119P+p.T122TI+p.K219T+p.I220L+p.D232E+p.L234F
Missense mutation 1.6 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S119P, T122TI, K219T, I220L, D232E, L234F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S17T+p.A23V+p.I72IV+p.T124A+p.G193E+p.V201I+p.I208M+p.E212SY+p.Q216H+p.I220L
Missense mutation 1.2 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S17T, A23V, I72IV, T124A, G193E, V201I, I208M, E212SY, Q216H, I220L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S17T+p.M50V+p.L101I+p.T112I+p.S119P+p.T124N+p.I135V+p.F181L+p.V201I+p.T206S+p.L242LF+p.A265V
Missense mutation 2.1 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S17T, M50V, L101I, T112I, S119P, T124N, I135V, F181L, V201I, T206S, L242LF, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.D25E+p.L68I+p.I73V+p.T124A+p.D167E+p.I220L
Missense mutation 2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, D25E, L68I, I73V, T124A, D167E, I220L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.D25E+p.V31I+p.I84M+p.Q95P+p.Y99F+p.L101I+p.T112A+p.S119P+p.K136N+p.K160R+p.V201I+p.I203M+p.I208L+p.T218S+p.L234H+p.D253E
Missense mutation 1.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, D25E, V31I, I84M, Q95P, Y99F, L101I, T112A, S119P, K136N, K160R, V201I, I203M, I208L, T218S, L234H, D253E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.K34KR+p.I72IV+p.I84M+p.A91T+p.L101I+p.T125V+p.V201I+p.K211KR+p.S230N+p.R262L+p.S283G
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, K34KR, I72IV, I84M, A91T, L101I, T125V, V201I, K211KR, S230N, R262L, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.L101I+p.I135V+p.K136T+p.Y194YH+p.T206S+p.I208L+p.T218S+p.S230N+p.D232DE
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, L101I, I135V, K136T, Y194YH, T206S, I208L, T218S, S230N, D232DE.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.M50I+p.S119P+p.T124A+p.I208IV+p.L241LF+p.D253E+p.D256E
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, M50I, S119P, T124A, I208IV, L241LF, D253E, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.N27NS+p.K34R+p.M50MI+p.L101I+p.S119P+p.T122TI+p.I135V+p.V165VI+p.K211R+p.D256E
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, N27NS, K34R, M50MI, L101I, S119P, T122TI, I135V, V165VI, K211R, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.N27S+p.A91T+p.E96D+p.L101I+p.S119R+p.T124S+p.T125A+p.I135IV+p.K156N+p.V165I+p.V201I+p.I208L+p.T210S+p.K211T+p.E212A+p.M275V+p.S283G
Missense mutation 2.5 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, N27S, A91T, E96D, L101I, S119R, T124S, T125A, I135IV, K156N, V165I, V201I, I208L, T210S, K211T, E212A, M275V, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.S39C+p.T124TA+p.V201I+p.S230N+p.R284RG
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, S39C, T124TA, V201I, S230N, R284RG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.V31I+p.L101I+p.K136N
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, V31I, L101I, K136N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24N+p.V31I+p.P58PT+p.K71KT+p.I72IV+p.I84IV+p.L101I+p.S119P+p.T122IV+p.T125A+p.I200IL+p.V201I+p.A205AT+p.I220L+p.D232E+p.S283SN
Missense mutation 1.5 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24N, V31I, P58PT, K71KT, I72IV, I84IV, L101I, S119P, T122IV, T125A, I200IL, V201I, A205AT, I220L, D232E, S283SN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S24SN+p.D25E+p.L101LI+p.S119P+p.T122TI+p.K136N
Missense mutation 1.3 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S24SN, D25E, L101LI, S119P, T122TI, K136N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S39C+p.L45Q+p.V201I+p.T218S
Missense mutation 1.3 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, S39C, L45Q, V201I, T218S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31I+p.M50MT+p.G70E+p.T97A+p.L101I+p.T112I+p.S119R+p.T124N+p.D167E+p.V201I+p.T206S+p.I208L+p.E212A+p.T218S+p.K240KR+p.S255N+p.D256E+p.R284G
Missense mutation 6.1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, V31I, M50MT, G70E, T97A, L101I, T112I, S119R, T124N, D167E, V201I, T206S, I208L, E212A, T218S, K240KR, S255N, D256E, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31I+p.M50TI+p.L101I+p.K111T+p.F181L+p.V201I+p.S283G
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, V31I, M50TI, L101I, K111T, F181L, V201I, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31I+p.P90PS+p.T112IV+p.I113IV+p.S119SG+p.T122I+p.A196P+p.V201I+p.K215KN+p.S230N
Missense mutation 1.5 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, V31I, P90PS, T112IV, I113IV, S119SG, T122I, A196P, V201I, K215KN, S230N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31I+p.V37I+p.V88VI+p.L101I+p.I113L+p.T124N+p.T125A+p.V201I+p.D229DG+p.D288X
Missense mutation 1.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, V31I, V37I, V88VI, L101I, I113L, T124N, T125A, V201I, D229DG, D288X.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31VI+p.L101I+p.K111T+p.T112IV+p.S119TP+p.T125A+p.V126A+p.Q148QR+p.V150A+p.V201I+p.Q209QP
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, V31VI, L101I, K111T, T112IV, S119TP, T125A, V126A, Q148QR, V150A, V201I, Q209QP.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31VI+p.L101I+p.K111T+p.T112IV+p.S119TP+p.T125A+p.V126A+p.V150A+p.V201I
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, V31VI, L101I, K111T, T112IV, S119TP, T125A, V126A, V150A, V201I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31VI+p.L101IV+p.K111T+p.S119SG+p.T122I+p.F181FI+p.V201I+p.T206PS
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, V31VI, L101IV, K111T, S119SG, T122I, F181FI, V201I, T206PS.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31VI+p.M50I+p.K111T+p.S119P+p.T124A+p.T206S
Missense mutation 2.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, V31VI, M50I, K111T, S119P, T124A, T206S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31VI+p.V32I+p.D41DN+p.L68V+p.I73V+p.Q95QR+p.L101LI+p.T125A+p.I135V+p.V201I+p.R284G
Missense mutation 2.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, V31VI, V32I, D41DN, L68V, I73V, Q95QR, L101LI, T125A, I135V, V201I, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V32VI+p.V37I+p.S39SC+p.D41DN+p.I60V+p.S119G+p.T122TI+p.T124N+p.T125A+p.V201I+p.I203M
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11D, V32VI, V37I, S39SC, D41DN, I60V, S119G, T122TI, T124N, T125A, V201I, I203M.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11ED+p.A21AT+p.V32VI+p.A33AT+p.G47GR+p.V88VI+p.A98AT+p.L101I+p.T112V+p.I113L
Missense mutation 1.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11ED, A21AT, V32VI, A33AT, G47GR, V88VI, A98AT, L101I, T112V, I113L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11ED+p.K14KR+p.A21T+p.M50I+p.A133AG+p.V176VL
Missense mutation 1.8 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11ED, K14KR, A21T, M50I, A133AG, V176VL.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11ED+p.R20K+p.L101I+p.K111T+p.T122I+p.T124A+p.V201I+p.R262RG+p.R263RG+p.R269RG+p.R284G+p.D286N
Missense mutation 1.5 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11ED, R20K, L101I, K111T, T122I, T124A, V201I, R262RG, R263RG, R269RG, R284G, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11ED+p.S17C+p.H67HP+p.S81SR+p.S119P+p.T124N+p.T125A+p.V126L+p.I182V+p.T206S
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11ED, S17C, H67HP, S81SR, S119P, T124N, T125A, V126L, I182V, T206S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11ED+p.V31I+p.L45I+p.L101I+p.S119P+p.I135V+p.F181L+p.T206S+p.K211R
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E11ED, V31I, L45I, L101I, S119P, I135V, F181L, T206S, K211R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E13ED+p.S17C+p.T124N+p.T125A+p.I182V+p.K219N+p.N222K+p.D288N
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E13ED, S17C, T124N, T125A, I182V, K219N, N222K, D288N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.H51Y+p.I72V+p.I113V+p.L234V
Missense mutation 2 Susceptible [12]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included H51Y, I72V, I113V, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72IV+p.L74I+p.E96D+p.L101LI+p.D256DE
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72IV, L74I, E96D, L101LI, D256DE.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.E138K+p.L234V
Missense mutation 0.7 Susceptible [9]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, E138K, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.G140S+p.L234V
Missense mutation 5 Susceptible [9]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, G140S, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.L234V+p.R263K
Missense mutation 3 Susceptible [12]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, L234V, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143A+p.G163R+p.L234V
Missense mutation 4.6 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143A, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143A+p.L234V
Missense mutation 2.5 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143A, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143C+p.G163R+p.L234V
Missense mutation 1.6 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143C, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143C+p.L234V
Missense mutation 1.5 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143C, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143C+p.S230R+p.L234V
Missense mutation 4.5 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143C, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143G+p.G163R+p.L234V
Missense mutation 3.2 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143G, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143G+p.L234V
Missense mutation 2.1 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143G, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143H+p.G163R+p.L234V
Missense mutation 1.8 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143H, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143H+p.L234V
Missense mutation 1.4 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143H, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143H+p.S230R+p.L234V
Missense mutation 2.5 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143H, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143R+p.G163R+p.L234V
Missense mutation 3 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143R, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143R+p.L234V
Missense mutation 2.9 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143R+p.S230R+p.L234V
Missense mutation 4.5 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143R, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143S+p.G163R+p.L234V
Missense mutation 2.4 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143S, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143S+p.L234V
Missense mutation 1.7 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143S, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.I113V+p.Y143A+p.L234V
Missense mutation 4.1 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, I113V, Y143A, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.I113V+p.Y143C+p.L234V
Missense mutation 2.2 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, I113V, Y143C, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.I113V+p.Y143G+p.L234V
Missense mutation 3.1 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, I113V, Y143G, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.I113V+p.Y143H+p.L234V
Missense mutation 2.3 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, I113V, Y143H, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.I113V+p.Y143R+p.L234V
Missense mutation 4.3 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, I113V, Y143R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.I113V+p.Y143S+p.L234V
Missense mutation 3 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, I113V, Y143S, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143C+p.L234V
Missense mutation 4.2 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143C, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143H+p.L234V
Missense mutation 4.4 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143H, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143S+p.L234V
Missense mutation 5.1 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143S, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.I113V+p.Y143A+p.L234V
Missense mutation 4 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, I113V, Y143A, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.I113V+p.Y143C+p.L234V
Missense mutation 2.2 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, I113V, Y143C, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.I113V+p.Y143G+p.L234V
Missense mutation 3 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, I113V, Y143G, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.I113V+p.Y143H+p.L234V
Missense mutation 1.9 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, I113V, Y143H, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.I113V+p.Y143R+p.L234V
Missense mutation 4.1 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, I113V, Y143R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.I113V+p.Y143S+p.L234V
Missense mutation 2.7 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, I113V, Y143S, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143C+p.L234V
Missense mutation 2.9 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143C, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143H+p.L234V
Missense mutation 3.9 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143H, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143S+p.L234V
Missense mutation 5 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143S, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143C+p.G163R+p.L234V
Missense mutation 4.9 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143C, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143C+p.L234V
Missense mutation 2.8 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143C, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143G+p.L234V
Missense mutation 4 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143G, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143H+p.G163R+p.L234V
Missense mutation 4.4 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143H, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143H+p.L234V
Missense mutation 2.6 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143H, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143H+p.S230R+p.L234V
Missense mutation 5.1 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143H, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143S+p.L234V
Missense mutation 3.5 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143S, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I84IM+p.L101I+p.S119T+p.K156KN+p.G193S+p.T206S+p.N254Q+p.S255SG+p.A265AV+p.S283G
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I84IM, L101I, S119T, K156KN, G193S, T206S, N254Q, S255SG, A265AV, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I89IV+p.L101I+p.V110VI+p.T124A+p.T125A+p.M154I+p.H171Y+p.R187K+p.T206S+p.K211R
Missense mutation 1.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I89IV, L101I, V110VI, T124A, T125A, M154I, H171Y, R187K, T206S, K211R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K111T+p.Q216H+p.D232DE+p.D256DE
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K111T, Q216H, D232DE, D256DE.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.D41N+p.L45Q+p.L101I+p.T125A+p.F181L+p.V201I+p.K219N+p.N222K+p.S283G
Missense mutation 1.5 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, D41N, L45Q, L101I, T125A, F181L, V201I, K219N, N222K, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.S17N+p.S24D+p.D25E+p.L28LI+p.S39C+p.G59GE+p.L101I+p.T124N+p.T125TA+p.V165I+p.L234LI+p.D286N
Missense mutation 1.5 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, S17N, S24D, D25E, L28LI, S39C, G59GE, L101I, T124N, T125TA, V165I, L234LI, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.S17SN+p.V31I+p.D41DN+p.L101I+p.K111KR+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136T+p.M154MI+p.T206S+p.L234I+p.S283G
Missense mutation 1.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, S17SN, V31I, D41DN, L101I, K111KR, T112V, T124A, T125A, G134N, I135V, K136T, M154MI, T206S, L234I, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.S17SN+p.V31VI+p.G106A+p.K111T+p.T124TA+p.E157Q+p.K160Q+p.V201I+p.D256E
Missense mutation 1.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, S17SN, V31VI, G106A, K111T, T124TA, E157Q, K160Q, V201I, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.S17X+p.M50I+p.V54I+p.E96D+p.L101I+p.T112S+p.T124N+p.T125A+p.A179AT+p.D288X
Missense mutation 1.7 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, S17X, M50I, V54I, E96D, L101I, T112S, T124N, T125A, A179AT, D288X.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.V31I+p.D41G+p.K42Q+p.L45Q+p.I84IM+p.F100Y+p.L101I+p.T112V+p.T124A+p.T125A+p.K136Q+p.V201I+p.L234I+p.D278A+p.S283G+p.R284G
Missense mutation 1.2 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, V31I, D41G, K42Q, L45Q, I84IM, F100Y, L101I, T112V, T124A, T125A, K136Q, V201I, L234I, D278A, S283G, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.V31I+p.G106A+p.T112I+p.T124A+p.T125A+p.G134D+p.K136Q+p.D167E+p.V201I+p.D229X+p.L234I+p.S283SG
Missense mutation 0.8 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, V31I, G106A, T112I, T124A, T125A, G134D, K136Q, D167E, V201I, D229X, L234I, S283SG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.D25E+p.K34R+p.M50MI+p.I72IV+p.F100Y+p.L101I+p.T112V+p.S119T+p.T124A+p.T125A+p.K136Q+p.V201I+p.T218I+p.L234I+p.D256DE+p.D278A+p.S283G
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, D25E, K34R, M50MI, I72IV, F100Y, L101I, T112V, S119T, T124A, T125A, K136Q, V201I, T218I, L234I, D256DE, D278A, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.K34R+p.V201I+p.T206S+p.N254Q+p.S255G+p.I267IV+p.M275MV
Missense mutation 1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, K34R, V201I, T206S, N254Q, S255G, I267IV, M275MV.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.L28I+p.S39C+p.A91T+p.T124S+p.G193E+p.V201I+p.T218S+p.S230N+p.D279N+p.S283G
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, L28I, S39C, A91T, T124S, G193E, V201I, T218S, S230N, D279N, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.R20K+p.S24N+p.D25E+p.V31I+p.G59E+p.I60V+p.L101I+p.T124A+p.T125TA+p.V165VI+p.K215KR+p.N222K
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, R20K, S24N, D25E, V31I, G59E, I60V, L101I, T124A, T125TA, V165VI, K215KR, N222K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.R20K+p.V31I+p.V32VA+p.A33AT+p.T97A+p.L101I+p.T112IV+p.T124A+p.T125A+p.G134N+p.I135V+p.G163Q+p.G193E+p.V201I+p.T206S+p.T218TI+p.Y227F+p.L234I+p.S255N+p.D256E+p.D279G+p.S283G
Missense mutation 1.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, R20K, V31I, V32VA, A33AT, T97A, L101I, T112IV, T124A, T125A, G134N, I135V, G163Q, G193E, V201I, T206S, T218TI, Y227F, L234I, S255N, D256E, D279G, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.R20RK+p.A91E+p.L101I+p.S119R+p.T124N+p.G193D+p.V201I+p.T206S+p.I208IL+p.D256DE+p.I268L+p.R269RK+p.D270DH
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, R20RK, A91E, L101I, S119R, T124N, G193D, V201I, T206S, I208IL, D256DE, I268L, R269RK, D270DH.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S17N+p.A23AV+p.V31I+p.C56Y+p.L101I+p.T112TI+p.T124S+p.T125A+p.I135V+p.K160Q+p.T218S+p.I251L
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, S17N, A23AV, V31I, C56Y, L101I, T112TI, T124S, T125A, I135V, K160Q, T218S, I251L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S17N+p.N18D+p.A21T+p.T124A+p.S195C+p.I203M+p.S230N+p.L234LH+p.D278A+p.R284G
Missense mutation 1.5 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, S17N, N18D, A21T, T124A, S195C, I203M, S230N, L234LH, D278A, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S17N+p.V31VI+p.I60M+p.L101I+p.T112V+p.T124A+p.I135IV+p.E138D+p.K188KR+p.V201I+p.A265V+p.S283G+p.R284RG+p.D286N
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, S17N, V31VI, I60M, L101I, T112V, T124A, I135IV, E138D, K188KR, V201I, A265V, S283G, R284RG, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S17SN+p.R20RK+p.V31I+p.D41DN+p.T66TI+p.E92EQ+p.L101I+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136T+p.R187RK+p.T206S+p.L234I+p.V249VI+p.S283G
Missense mutation 8.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, S17SN, R20RK, V31I, D41DN, T66TI, E92EQ, L101I, T112V, T124A, T125A, G134N, I135V, K136T, R187RK, T206S, L234I, V249VI, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S24N+p.L101V+p.K111R+p.T112V+p.T124A+p.V126M+p.K160Q+p.D167DE+p.V201I+p.K211R+p.S230N
Missense mutation 1.4 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, S24N, L101V, K111R, T112V, T124A, V126M, K160Q, D167DE, V201I, K211R, S230N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.V31I+p.L101I+p.T112I+p.T124A+p.T125A+p.G134N+p.I135V+p.K136T+p.I162IV+p.V201I+p.I203M+p.T206S+p.Y227F+p.L234I+p.S255N+p.D256E+p.S283G
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, V31I, L101I, T112I, T124A, T125A, G134N, I135V, K136T, I162IV, V201I, I203M, T206S, Y227F, L234I, S255N, D256E, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.V31I+p.L45LV+p.T124X+p.T125TA+p.L172LP+p.K215N+p.S230N+p.R231K+p.D253E+p.N254Q+p.S255G+p.D256E
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, V31I, L45LV, T124X, T125TA, L172LP, K215N, S230N, R231K, D253E, N254Q, S255G, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.V31I+p.S39C+p.L45Q+p.I84IM+p.K111T+p.V201I+p.K211KR+p.S230N+p.L234I+p.I251IT+p.D253DAE+p.N254ND+p.D256E
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, V31I, S39C, L45Q, I84IM, K111T, V201I, K211KR, S230N, L234I, I251IT, D253DAE, N254ND, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.V31VA+p.C56S+p.L101I+p.V201I+p.I208IL+p.I220L+p.Y227F+p.D256E+p.V281VA
Missense mutation 1.2 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, V31VA, C56S, L101I, V201I, I208IL, I220L, Y227F, D256E, V281VA.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.V32I+p.L101I+p.T124N+p.M154MI+p.N155NH+p.V201I+p.N222H+p.S230N+p.D256E
Missense mutation 1.5 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, V32I, L101I, T124N, M154MI, N155NH, V201I, N222H, S230N, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.Y99H+p.L101I+p.I135V+p.E157Q+p.G193D+p.S195C+p.A265V
Missense mutation 1.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, Y99H, L101I, I135V, E157Q, G193D, S195C, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K156N+p.I161L+p.V201I+p.T218S+p.Q221E+p.N222K
Missense mutation 1.3 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K156N, I161L, V201I, T218S, Q221E, N222K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K34R+p.L101LI+p.T112V+p.T125TA+p.I135IV+p.E138ED+p.V201I+p.L234I
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K34R, L101LI, T112V, T125TA, I135IV, E138ED, V201I, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K34R+p.T66TA+p.I72IV+p.L74MV+p.L101I+p.S119T+p.T206S+p.T218S+p.M275V
Missense mutation 2.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K34R, T66TA, I72IV, L74MV, L101I, S119T, T206S, T218S, M275V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7KE+p.S17N+p.V31VI+p.T124A+p.K160N+p.F223FL+p.A282AT
Missense mutation 1.8 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7KE, S17N, V31VI, T124A, K160N, F223FL, A282AT.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7KE+p.T66TP+p.I84IM+p.S119T+p.M154L+p.K160KI+p.V201I+p.T218S
Missense mutation 1.3 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7KE, T66TP, I84IM, S119T, M154L, K160KI, V201I, T218S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7KQ+p.L101IV+p.T124X+p.T125A+p.V126IML+p.K156KN+p.L234I
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7KQ, L101IV, T124X, T125A, V126IML, K156KN, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7KR+p.E11D+p.D25E+p.L101I+p.K111R+p.S119P+p.T122I+p.T124A+p.M154L+p.D256E
Missense mutation 1.5 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7KR, E11D, D25E, L101I, K111R, S119P, T122I, T124A, M154L, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7KR+p.E11D+p.K14R+p.A21T+p.A23V+p.D25DE+p.I72IV+p.L101I+p.K103KR+p.S119T
Missense mutation 1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7KR, E11D, K14R, A21T, A23V, D25DE, I72IV, L101I, K103KR, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7KR+p.L28I+p.P30S+p.S39C+p.L45LS+p.M50MT+p.L101LI+p.T112A+p.N117NS+p.V201I+p.I220L+p.D253E+p.S255SN
Missense mutation 1.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7KR, L28I, P30S, S39C, L45LS, M50MT, L101LI, T112A, N117NS, V201I, I220L, D253E, S255SN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7KR+p.S17N+p.R20K+p.A23AV+p.S119G+p.T122V+p.T124A+p.T125A+p.V201I+p.T206S+p.D288N
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7KR, S17N, R20K, A23AV, S119G, T122V, T124A, T125A, V201I, T206S, D288N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7R+p.D25E+p.H51HQ+p.F100Y+p.L101I+p.T112V+p.T124A+p.T125A+p.K136Q+p.V165I+p.V201I+p.T218I+p.K219Q+p.L234I+p.S255G+p.R269K+p.D278A+p.S283G
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7R, D25E, H51HQ, F100Y, L101I, T112V, T124A, T125A, K136Q, V165I, V201I, T218I, K219Q, L234I, S255G, R269K, D278A, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7R+p.E11D+p.D25E+p.V31I+p.M50MT+p.I72IV+p.L101I+p.K111AT+p.S119SG+p.T122TI+p.T124TN+p.E138ED+p.K188KR+p.V201I+p.Q216H+p.A265AV
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7R, E11D, D25E, V31I, M50MT, I72IV, L101I, K111AT, S119SG, T122TI, T124TN, E138ED, K188KR, V201I, Q216H, A265AV.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7R+p.L28I+p.S39C+p.D64DN+p.P90PS+p.A91AS+p.T124A+p.I141IV+p.V201VI+p.I203IM+p.T206TS+p.I208L+p.Q216H+p.L234LI
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7R, L28I, S39C, D64DN, P90PS, A91AS, T124A, I141IV, V201VI, I203IM, T206TS, I208L, Q216H, L234LI.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7R+p.L28I+p.S39C+p.M50I+p.L101I+p.F181L+p.V201I+p.A205S+p.K215N+p.Q221R+p.N222K
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7R, L28I, S39C, M50I, L101I, F181L, V201I, A205S, K215N, Q221R, N222K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7R+p.S17N+p.L28I+p.V151I+p.Y227F+p.D253Y+p.D256E+p.R284G
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7R, S17N, L28I, V151I, Y227F, D253Y, D256E, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7R+p.S17N+p.T124NS+p.I220M+p.Y227F+p.A265V
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7R, S17N, T124NS, I220M, Y227F, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L101I+p.G106GA+p.T124A+p.K156N+p.V201I+p.I217V+p.P261S+p.R262L
Missense mutation 0.8 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L101I, G106GA, T124A, K156N, V201I, I217V, P261S, R262L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L101I+p.K111T+p.I135V+p.K173R+p.V176L+p.A205T+p.K211R+p.T218S+p.S230N+p.D256E+p.D270E
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L101I, K111T, I135V, K173R, V176L, A205T, K211R, T218S, S230N, D256E, D270E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L101I+p.K156N+p.I208L
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L101I, K156N, I208L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L101I+p.T124A+p.V201I+p.T206TS+p.K211R+p.K215N
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L101I, T124A, V201I, T206TS, K211R, K215N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L101I+p.T124TA+p.T125A+p.I135V+p.F181L+p.K188R+p.G193R+p.V201I+p.T206S+p.T218I+p.A265V+p.V281M
Missense mutation 1.1 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L101I, T124TA, T125A, I135V, F181L, K188R, G193R, V201I, T206S, T218I, A265V, V281M.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L2LP+p.E11D+p.K14R+p.V32I+p.V201I+p.I208L+p.E212A+p.D232E+p.L234F+p.S283SG
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L2LP, E11D, K14R, V32I, V201I, I208L, E212A, D232E, L234F, S283SG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L45LV+p.L101I+p.G163E+p.V165VI+p.S195C+p.Q216H+p.K219Q+p.D278A
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L45LV, L101I, G163E, V165VI, S195C, Q216H, K219Q, D278A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M22MI+p.L45V+p.E92EG+p.L101I+p.G163E+p.S195C+p.Q216H+p.K219Q+p.D278A
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M22MI, L45V, E92EG, L101I, G163E, S195C, Q216H, K219Q, D278A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I+p.K156N+p.V201I
Missense mutation 1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50I, K156N, V201I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I+p.K173KR+p.K215N+p.I220L+p.D256E
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50I, K173KR, K215N, I220L, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I+p.L101I+p.G193E+p.V201I+p.S230N+p.D256E+p.D286N
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50I, L101I, G193E, V201I, S230N, D256E, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I+p.V151I+p.L234LF
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50I, V151I, L234LF.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50L+p.T112V+p.T124TA+p.V201I+p.I203IM+p.T206TS+p.T218S+p.Q221R
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50L, T112V, T124TA, V201I, I203IM, T206TS, T218S, Q221R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50MI+p.L101I+p.T112V+p.I220V+p.D253E
Missense mutation 0.9 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50MI, L101I, T112V, I220V, D253E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50MI+p.T125A+p.I135V+p.M154MI+p.I162IV+p.V201I+p.K215N+p.L234I
Missense mutation 1.3 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50MI, T125A, I135V, M154MI, I162IV, V201I, K215N, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50MIT+p.I72IV+p.T112I+p.T124TA+p.V201I+p.T206TS+p.K215KN
Missense mutation 1.5 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50MIT, I72IV, T112I, T124TA, V201I, T206TS, K215KN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50TI+p.G70D+p.L101I+p.I113IV+p.S119R+p.T124N+p.T125A+p.I135V+p.F181L+p.T206S+p.I251IV+p.D256E
Missense mutation 2.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50TI, G70D, L101I, I113IV, S119R, T124N, T125A, I135V, F181L, T206S, I251IV, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.P30A+p.A49AS+p.P90PS+p.L101I+p.T112A+p.S123C+p.T124N+p.V201I+p.T218I+p.D256E+p.S283G
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included P30A, A49AS, P90PS, L101I, T112A, S123C, T124N, V201I, T218I, D256E, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.P30PL+p.L101LI+p.A105AT+p.K111TA+p.S119G+p.T122I+p.T125A+p.V201I
Missense mutation 1.7 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included P30PL, L101LI, A105AT, K111TA, S119G, T122I, T125A, V201I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.P90PS+p.L101I+p.M154L+p.V201VI
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included P90PS, L101I, M154L, V201VI.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.P90S+p.E212A+p.K215N+p.I220L+p.S230SN
Missense mutation 1.8 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included P90S, E212A, K215N, I220L, S230SN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20K+p.K156KR+p.I200IM+p.V201I+p.D270DN
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R20K, K156KR, I200IM, V201I, D270DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20K+p.L101I+p.K111T+p.T122I+p.T124A+p.V201I+p.R284RG+p.D286N
Missense mutation 1.3 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R20K, L101I, K111T, T122I, T124A, V201I, R284RG, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20K+p.L101I+p.K160KR+p.G193E+p.V201VI+p.E212EA+p.D256E
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R20K, L101I, K160KR, G193E, V201VI, E212EA, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20K+p.L45I+p.K156N+p.S230SN+p.L234LH
Missense mutation 1.3 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R20K, L45I, K156N, S230SN, L234LH.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20RK+p.I84IV+p.L101I+p.T112TI+p.T125TA+p.M154I+p.V165I+p.H171L+p.K211R
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R20RK, I84IV, L101I, T112TI, T125TA, M154I, V165I, H171L, K211R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20RK+p.L101I+p.K103R+p.S119G+p.T122I+p.T124N+p.G193GE
Missense mutation 1.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R20RK, L101I, K103R, S119G, T122I, T124N, G193GE.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20RK+p.V31I+p.E48EK+p.L101I+p.I113IV+p.S119ST+p.T125A+p.M154L+p.K173R+p.F181L+p.G193E+p.T206S+p.T210I+p.T218I+p.I220V+p.L234H+p.D279G
Missense mutation 2.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R20RK, V31I, E48EK, L101I, I113IV, S119ST, T125A, M154L, K173R, F181L, G193E, T206S, T210I, T218I, I220V, L234H, D279G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20RK+p.V31I+p.T112A+p.T124S+p.T125A+p.K127KR+p.V165I+p.A205S+p.E287EK
Missense mutation 1.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R20RK, V31I, T112A, T124S, T125A, K127KR, V165I, A205S, E287EK.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119R+p.T125S+p.G193E+p.L234I+p.N254S+p.S255G+p.D279G
Missense mutation 1.9 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S119R, T125S, G193E, L234I, N254S, S255G, D279G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S147G
Missense mutation 4.1 Susceptible [11]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S147G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17C+p.A23AT+p.M50I+p.L101I+p.T112R+p.T124A+p.T125A+p.E157Q+p.K160Q+p.K219N+p.N222K+p.S230SN
Missense mutation 2.4 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17C, A23AT, M50I, L101I, T112R, T124A, T125A, E157Q, K160Q, K219N, N222K, S230SN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17C+p.G163E+p.K188R+p.K211R+p.Q216N
Missense mutation 1.4 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17C, G163E, K188R, K211R, Q216N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17C+p.I72IV+p.K111KN+p.K173KR
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17C, I72IV, K111KN, K173KR.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17C+p.T112R+p.T125A+p.K188R+p.T218I+p.A265V
Missense mutation 1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17C, T112R, T125A, K188R, T218I, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.A23AS+p.V31I+p.G47GR+p.E48EG+p.I72IN+p.I84IM+p.L101I+p.K103KR+p.T124S+p.T125A+p.K156N+p.G189GR+p.E198D+p.V201I+p.T206S+p.D232E+p.A265V
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, A23AS, V31I, G47GR, E48EG, I72IN, I84IM, L101I, K103KR, T124S, T125A, K156N, G189GR, E198D, V201I, T206S, D232E, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.A23AT+p.N27G+p.L28I+p.L45Q+p.D256DE
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, A23AT, N27G, L28I, L45Q, D256DE.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.A23AV+p.L101I+p.K211Q+p.T218TS+p.D256E
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, A23AV, L101I, K211Q, T218TS, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.A91T+p.L101I+p.T124A+p.K156N+p.V165VI+p.V201I+p.T218TS+p.Y227F+p.D229E+p.D253Y+p.D256E+p.A265V
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, A91T, L101I, T124A, K156N, V165VI, V201I, T218TS, Y227F, D229E, D253Y, D256E, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.D25DE+p.N27NS+p.G59GE+p.I72IV+p.V77VI+p.V79VI+p.I84IM+p.V88VI+p.L101I+p.S119T+p.T124S+p.T125A+p.T206S
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, D25DE, N27NS, G59GE, I72IV, V77VI, V79VI, I84IM, V88VI, L101I, S119T, T124S, T125A, T206S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.D25E+p.M50I+p.L101I+p.T124TA+p.K156N+p.I204IL+p.Q221S+p.N222K+p.D253E
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, D25E, M50I, L101I, T124TA, K156N, I204IL, Q221S, N222K, D253E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.E96D+p.L101I+p.T124A+p.G140GS+p.Q148QH+p.V165I+p.F181FL+p.G193D+p.Y194YC+p.V201I+p.S255K+p.I268L+p.D270H
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, E96D, L101I, T124A, G140GS, Q148QH, V165I, F181FL, G193D, Y194YC, V201I, S255K, I268L, D270H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.E96D+p.L101I+p.T124A+p.V165I+p.F181FL+p.G193GDE+p.Y194YC+p.V201I+p.S255K+p.A265AV+p.I268IL+p.R269RK+p.D270DH
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, E96D, L101I, T124A, V165I, F181FL, G193GDE, Y194YC, V201I, S255K, A265AV, I268IL, R269RK, D270DH.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.G59A+p.L101I+p.T124S+p.T125A+p.K136N+p.K160KR+p.V201I+p.I203M+p.S255R
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, G59A, L101I, T124S, T125A, K136N, K160KR, V201I, I203M, S255R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.I72IV+p.K111T+p.T124A+p.D253DE+p.D256E
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72IV, K111T, T124A, D253DE, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.I84IV+p.E87ED+p.L101I+p.K156N+p.D256E
Missense mutation 0.9 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I84IV, E87ED, L101I, K156N, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.I84L+p.T112I+p.T124S+p.T125A+p.V201I+p.I203M+p.L234I+p.D256E+p.A265V
Missense mutation 0.8 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I84L, T112I, T124S, T125A, V201I, I203M, L234I, D256E, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.K111KR+p.T125A+p.G193E+p.V201I+p.D232E+p.D286N
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, K111KR, T125A, G193E, V201I, D232E, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.K34KR+p.M50L+p.I84IM+p.T124A+p.T125A+p.V201VI+p.A205S+p.T206S+p.I208IL+p.K211KR+p.E212EA
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, K34KR, M50L, I84IM, T124A, T125A, V201VI, A205S, T206S, I208IL, K211KR, E212EA.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.K34R+p.G59GE+p.I72IV+p.T112TI+p.I113IV+p.S119P+p.T124N+p.T125A+p.K136KT+p.V201I+p.S230N+p.D256E+p.Q274QK+p.D278DA+p.S283SG+p.R284RG
Missense mutation 1.6 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, K34R, G59GE, I72IV, T112TI, I113IV, S119P, T124N, T125A, K136KT, V201I, S230N, D256E, Q274QK, D278DA, S283SG, R284RG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.K34R+p.L74V+p.L101I+p.T124A+p.K173R+p.A265V
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, K34R, L74V, L101I, T124A, K173R, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.L101I+p.T112I+p.T124N+p.G163E+p.V201I+p.A205S+p.T206S+p.D256E
Missense mutation 1.2 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, L101I, T112I, T124N, G163E, V201I, A205S, T206S, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.L158LS+p.K219Q+p.I220L+p.S255K
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, L158LS, K219Q, I220L, S255K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.L28I+p.D41E+p.L45V+p.M50L+p.T112I+p.A128T+p.I220L+p.Q221H+p.N222T+p.D270H+p.R284G
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, L28I, D41E, L45V, M50L, T112I, A128T, I220L, Q221H, N222T, D270H, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.L28I+p.L45I+p.L101I+p.S119G+p.T122I+p.T124A+p.T125A+p.G163E+p.T218S
Missense mutation 1.8 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, L28I, L45I, L101I, S119G, T122I, T124A, T125A, G163E, T218S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.L28I+p.P30A+p.G59E+p.I60V+p.L101I+p.T124A+p.V201I+p.T206S+p.D270DN
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, L28I, P30A, G59E, I60V, L101I, T124A, V201I, T206S, D270DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.L28I+p.S39C+p.M50MI+p.T66TA+p.T124TA+p.S147SG+p.V201I+p.K211Q
Missense mutation 4.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, L28I, S39C, M50MI, T66TA, T124TA, S147SG, V201I, K211Q.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.L28I+p.S39SC+p.T124A+p.T125A+p.G163E+p.V201I+p.K240R
Missense mutation 0.9 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, L28I, S39SC, T124A, T125A, G163E, V201I, K240R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.L28I+p.V32VI+p.S39C+p.M50MI+p.E138EK+p.V201I+p.K211Q
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, L28I, V32VI, S39C, M50MI, E138EK, V201I, K211Q.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.L28LI+p.S39C+p.L101LI+p.T124N+p.T125A+p.I135IV+p.F181FL+p.I191IM+p.G193GE+p.V201I+p.T206S+p.K219N+p.N222K+p.A265AV+p.I268IL+p.D270DH
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, L28LI, S39C, L101LI, T124N, T125A, I135IV, F181FL, I191IM, G193GE, V201I, T206S, K219N, N222K, A265AV, I268IL, D270DH.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.L45V+p.I73V+p.P90S+p.L101I+p.T124N+p.G163H+p.I208L+p.I220L+p.D256E+p.S283G
Missense mutation 1.4 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, L45V, I73V, P90S, L101I, T124N, G163H, I208L, I220L, D256E, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.M50I+p.L101I+p.T124A+p.G163E+p.G193E+p.V201I+p.D279N
Missense mutation 1 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, M50I, L101I, T124A, G163E, G193E, V201I, D279N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.M50MI+p.L63M+p.I113IV+p.T124A+p.T125A+p.K215N+p.I220L+p.D279G
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, M50MI, L63M, I113IV, T124A, T125A, K215N, I220L, D279G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.R20RK+p.V31I+p.M50I+p.T124A+p.K156N+p.V165I+p.F181FL+p.V201I+p.S255K+p.I268L+p.D270DN
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, R20RK, V31I, M50I, T124A, K156N, V165I, F181FL, V201I, S255K, I268L, D270DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.R20RK+p.V31I+p.T124A+p.E157Q+p.K160Q+p.V201I+p.K211R+p.L213S+p.N222K+p.S230SN+p.S255G+p.A265V+p.R284G
Missense mutation 0.9 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, R20RK, V31I, T124A, E157Q, K160Q, V201I, K211R, L213S, N222K, S230SN, S255G, A265V, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.S24SG+p.F100FC+p.L101I+p.T112I+p.T124A+p.T125A+p.G134N+p.K136T+p.V201I+p.T206S+p.Y227F+p.L234I+p.S255N+p.D256E+p.S283G
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, S24SG, F100FC, L101I, T112I, T124A, T125A, G134N, K136T, V201I, T206S, Y227F, L234I, S255N, D256E, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.S39C+p.D41DG+p.V79VI+p.L101I+p.T112TI+p.T124N+p.I203M+p.T206S+p.Q209QR+p.D253DE+p.D256E+p.D279DN
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, S39C, D41DG, V79VI, L101I, T112TI, T124N, I203M, T206S, Q209QR, D253DE, D256E, D279DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.S39C+p.L101I+p.T112V+p.T124A+p.V201I+p.T218S+p.I268L
Missense mutation 1 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, S39C, L101I, T112V, T124A, V201I, T218S, I268L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31I+p.I60L+p.T124N+p.T125A+p.K173R+p.I182V+p.K215KN+p.Y227F+p.D253Y+p.D256E
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, I60L, T124N, T125A, K173R, I182V, K215KN, Y227F, D253Y, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31I+p.I72IV+p.L101I+p.K111T+p.T124A+p.V165I+p.F181L+p.D256E
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, I72IV, L101I, K111T, T124A, V165I, F181L, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31I+p.I72IV+p.L101I+p.T124A+p.E157Q+p.K160Q+p.D232E+p.A265V
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, I72IV, L101I, T124A, E157Q, K160Q, D232E, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31I+p.L101I+p.T124N+p.I135V+p.G163E+p.K173R+p.V201I+p.A205S+p.S230N
Missense mutation 1.5 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, L101I, T124N, I135V, G163E, K173R, V201I, A205S, S230N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31I+p.M50MI+p.I72IV+p.L101I+p.T124A+p.K136KN+p.N155NH+p.E157Q+p.K160Q+p.D232E+p.A265V
Missense mutation 2.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, M50MI, I72IV, L101I, T124A, K136KN, N155NH, E157Q, K160Q, D232E, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31I+p.V32I+p.S39C+p.L101I+p.T112I+p.T124N+p.V201I+p.A205S+p.T206S+p.K211R+p.S230N
Missense mutation 1.5 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, V32I, S39C, L101I, T112I, T124N, V201I, A205S, T206S, K211R, S230N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31VI+p.M50MI+p.L101I+p.T112TI+p.T124NS+p.T125V+p.G163E
Missense mutation 1.3 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31VI, M50MI, L101I, T112TI, T124NS, T125V, G163E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31VI+p.M50MI+p.L101I+p.T112V+p.T124N+p.I135V+p.G193D+p.S195C+p.D207DG+p.D256E+p.A265V+p.D278A
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31VI, M50MI, L101I, T112V, T124N, I135V, G193D, S195C, D207DG, D256E, A265V, D278A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31VI+p.S57G+p.K111KR+p.T124N+p.T125TA+p.K211KQ+p.T218S+p.K219N+p.N222K+p.S230N
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31VI, S57G, K111KR, T124N, T125TA, K211KQ, T218S, K219N, N222K, S230N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31VI+p.V54I+p.L101I+p.T124A+p.T125A+p.I208L+p.K215N+p.L234I+p.N254K+p.S255SG+p.A265V
Missense mutation 1 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31VI, V54I, L101I, T124A, T125A, I208L, K215N, L234I, N254K, S255SG, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31VIM+p.I72IT+p.I84IL+p.V88VL+p.T124S+p.T125TA+p.K156N+p.I203M+p.D256E
Missense mutation 1.5 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31VIM, I72IT, I84IL, V88VL, T124S, T125TA, K156N, I203M, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V54I+p.T112I+p.T124N+p.V201I+p.D256E
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V54I, T112I, T124N, V201I, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17SN+p.L101LI+p.V151VI+p.M154I+p.I203IV
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17SN, L101LI, V151VI, M154I, I203IV.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17SN+p.S24SN+p.M50MI+p.T124TA+p.T125A+p.K156N+p.E157Q+p.K211Q+p.D256E+p.S283SG+p.R284G+p.D288N
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17SN, S24SN, M50MI, T124TA, T125A, K156N, E157Q, K211Q, D256E, S283SG, R284G, D288N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17SN+p.V31I+p.T115TA+p.T124N+p.T125A+p.A205AS+p.T206TS+p.D207DE+p.D232E+p.L234I+p.D253E+p.D256E
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17SN, V31I, T115TA, T124N, T125A, A205AS, T206TS, D207DE, D232E, L234I, D253E, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S24G+p.D25E+p.L28I+p.L45V+p.V201I+p.S230N+p.R269RG+p.R284G
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24G, D25E, L28I, L45V, V201I, S230N, R269RG, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S24G+p.L101I+p.T124A+p.S153A+p.M154I+p.I200M+p.V201I+p.Q216H+p.Q221R+p.D256E
Missense mutation 1.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24G, L101I, T124A, S153A, M154I, I200M, V201I, Q216H, Q221R, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S24G+p.S39C+p.V79A+p.T97TA+p.L101I+p.T124N+p.V201I+p.Q216R+p.K219Q+p.A265V+p.S283G
Missense mutation 1 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24G, S39C, V79A, T97TA, L101I, T124N, V201I, Q216R, K219Q, A265V, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S24SG+p.C56Y+p.S57N+p.K156N+p.K211R+p.L234I
Missense mutation 0.8 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24SG, C56Y, S57N, K156N, K211R, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S24SN+p.T112A+p.T125A+p.F181FL+p.E212A+p.Q216H+p.T218S+p.K219N
Missense mutation 1.7 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24SN, T112A, T125A, F181FL, E212A, Q216H, T218S, K219N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S24T+p.V31VI+p.L101I+p.K111T+p.T112A+p.T124A+p.T125TA+p.I135V+p.I162IV+p.F181L+p.E212S+p.K215N+p.Q216H+p.T218S+p.S230N
Missense mutation 1.6 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24T, V31VI, L101I, K111T, T112A, T124A, T125TA, I135V, I162IV, F181L, E212S, K215N, Q216H, T218S, S230N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S39C+p.D41DN+p.M50I+p.L101I+p.T124A+p.T125A+p.V201VI+p.D253E+p.S283G+p.R284G
Missense mutation 1.2 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S39C, D41DN, M50I, L101I, T124A, T125A, V201VI, D253E, S283G, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S39C+p.G59E+p.T124N+p.T125A+p.V126L+p.M154L+p.V201I
Missense mutation 1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S39C, G59E, T124N, T125A, V126L, M154L, V201I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S39C+p.I72IV+p.Y99H+p.V201I
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S39C, I72IV, Y99H, V201I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S39C+p.M50I+p.L101I+p.S119P+p.M154L+p.K173KR+p.Q177QL+p.V201I+p.T206S+p.T218S
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S39C, M50I, L101I, S119P, M154L, K173KR, Q177QL, V201I, T206S, T218S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S39SC+p.L45LI+p.L101I+p.V201I+p.K219Q+p.D256E+p.D286DN
Missense mutation 0.9 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S39SC, L45LI, L101I, V201I, K219Q, D256E, D286DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S39SC+p.M50I+p.S119P+p.T125A+p.M154L+p.D167E+p.V201I+p.K211R+p.T218I
Missense mutation 1.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S39SC, M50I, S119P, T125A, M154L, D167E, V201I, K211R, T218I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S39SN+p.P90PS+p.L101I+p.M154I+p.V201I+p.T210TI+p.K215N+p.L234LF+p.L242LF+p.D279G
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S39SN, P90PS, L101I, M154I, V201I, T210TI, K215N, L234LF, L242LF, D279G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S57SG+p.G59E+p.L101I+p.T206S+p.D256E+p.S283SG
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S57SG, G59E, L101I, T206S, D256E, S283SG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S81SR+p.A91T+p.L101I+p.S119P+p.T122I+p.T124TA+p.N144NH+p.I208M+p.S255G+p.S283G+p.R284G
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S81SR, A91T, L101I, S119P, T122I, T124TA, N144NH, I208M, S255G, S283G, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T124A+p.T125A+p.I135V+p.D167E+p.R284G
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T124A, T125A, I135V, D167E, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T124A+p.T210I+p.K211R+p.A265V+p.D279G
Missense mutation 1.7 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T124A, T210I, K211R, A265V, D279G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.T112A+p.T125A+p.V126L+p.Q148QR+p.M154I+p.L234I
Missense mutation 9.8 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, T112A, T125A, V126L, Q148QR, M154I, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.D55DN+p.I72IV+p.L101I+p.K103R+p.T112I+p.T124A+p.T125A+p.V126VI+p.V201I+p.A205T+p.K211R+p.I220L+p.Y227F+p.D253Y+p.A265V+p.R284G
Missense mutation 1.2 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, D55DN, I72IV, L101I, K103R, T112I, T124A, T125A, V126VI, V201I, A205T, K211R, I220L, Y227F, D253Y, A265V, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.E92EQ+p.T112AV+p.T124S+p.T125A+p.K127KR+p.V165I+p.A205S
Missense mutation 2.8 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, E92EQ, T112AV, T124S, T125A, K127KR, V165I, A205S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.I72IV+p.G106A+p.T125TA+p.S230N+p.D232E
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, I72IV, G106A, T125TA, S230N, D232E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.I84IM+p.L101I+p.K111T+p.I135V+p.V201I+p.T206S+p.K211R+p.E212T+p.K219N
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, I84IM, L101I, K111T, I135V, V201I, T206S, K211R, E212T, K219N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.K136N+p.V201I+p.I203IML+p.S230N+p.D256E+p.S283ST
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, K136N, V201I, I203IML, S230N, D256E, S283ST.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.L101I+p.G118GD+p.S119G+p.T122I+p.T124N+p.F181L+p.V201I+p.I220IL+p.S283G+p.R284G
Missense mutation 2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, L101I, G118GD, S119G, T122I, T124N, F181L, V201I, I220IL, S283G, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.L101I+p.I203IM+p.T206S+p.K211R+p.Q216H+p.I268L+p.D270H+p.R284G
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, L101I, I203IM, T206S, K211R, Q216H, I268L, D270H, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.L101I+p.S119G+p.T122I+p.T124N+p.F181L+p.V201I+p.I220IL+p.S283G+p.R284G
Missense mutation 2.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, L101I, S119G, T122I, T124N, F181L, V201I, I220IL, S283G, R284G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.L101I+p.T112I+p.T124A+p.T125V+p.I135V+p.G163QH+p.A179G+p.F181L+p.V201I+p.T206S+p.L234I+p.D256E+p.I268L+p.D270H
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, L101I, T112I, T124A, T125V, I135V, G163QH, A179G, F181L, V201I, T206S, L234I, D256E, I268L, D270H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.M50I+p.C65CG+p.I72IV+p.N117NK+p.T124N+p.T125A+p.E138D+p.D167E+p.V201I+p.A265V+p.D286N
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, M50I, C65CG, I72IV, N117NK, T124N, T125A, E138D, D167E, V201I, A265V, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.M50I+p.L63I+p.L74V+p.E96D+p.L101I+p.T124N+p.T125A+p.G193E+p.V201I+p.I208IL+p.K211KR+p.E212X+p.T218S+p.S230N+p.D232E+p.D256E
Missense mutation 1.3 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, M50I, L63I, L74V, E96D, L101I, T124N, T125A, G193E, V201I, I208IL, K211KR, E212X, T218S, S230N, D232E, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.M50I+p.T124A+p.K188KR+p.T206S+p.Y227F+p.A265V
Missense mutation 1.5 Susceptible [5]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, M50I, T124A, K188KR, T206S, Y227F, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.M50MI+p.S119P+p.T122I+p.D256E
Missense mutation 1.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, M50MI, S119P, T122I, D256E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.M50MT+p.L101I+p.K111Q+p.P142PS+p.P261PS+p.A265V
Missense mutation 0.9 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, M50MT, L101I, K111Q, P142PS, P261PS, A265V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.P90PS+p.T112AV+p.T124A+p.M154L+p.K211R+p.T218S+p.S230N+p.S283G
Missense mutation 1.5 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, P90PS, T112AV, T124A, M154L, K211R, T218S, S230N, S283G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.S39C+p.P90PS+p.E96EG+p.T124N+p.V201I+p.K215Q+p.T218S+p.S230N+p.D232E+p.L234H+p.D253E+p.N254D+p.C280CR
Missense mutation 1.5 Susceptible [6]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, S39C, P90PS, E96EG, T124N, V201I, K215Q, T218S, S230N, D232E, L234H, D253E, N254D, C280CR.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31I+p.T124TN+p.T125V+p.K156N+p.D167E
Missense mutation 1.6 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31I, T124TN, T125V, K156N, D167E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31VA+p.T124TA+p.T125TA+p.V201I+p.S230N+p.L234I+p.A265V+p.D270N+p.R284RG
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31VA, T124TA, T125TA, V201I, S230N, L234I, A265V, D270N, R284RG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V31VMI+p.M50I+p.I72X+p.L101I+p.K103KR+p.H114HY+p.I135IV+p.V176L+p.A205S+p.T206S+p.T218S+p.Y227F+p.S255N+p.D256E+p.S283SG
Missense mutation 1.1 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V31VMI, M50I, I72X, L101I, K103KR, H114HY, I135IV, V176L, A205S, T206S, T218S, Y227F, S255N, D256E, S283SG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V54I+p.L101I+p.T124N+p.T125M+p.G163T+p.L234LF+p.L241LF+p.L242LF+p.D253E+p.N254SG
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V54I, L101I, T124N, T125M, G163T, L234LF, L241LF, L242LF, D253E, N254SG.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Y143C
Missense mutation 1.1 Susceptible [11]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143C.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Y143H
Missense mutation 1.2 Susceptible [11]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Y143R
Missense mutation 2.1 Susceptible [11]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138A+p.D232N
Missense mutation 1.3 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E297Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138K+p.D232N
Missense mutation 1.4 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E298Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E157K+p.D232N
Missense mutation 1.4 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E299Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I
Missense mutation 1.5 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E300Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119G
Missense mutation 1.5 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E301Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.A128T+p.D232N
Missense mutation 1.5 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E302Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G163K+p.D232N
Missense mutation 1.5 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E303Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119T
Missense mutation 1.6 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E304Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143H+p.D232N
Missense mutation 1.6 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E305Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E170A+p.D232N
Missense mutation 1.6 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E306Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.Q95R+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.7 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E308Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G163R
Missense mutation 1.8 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E309Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.L68V+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.8 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E310Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119P
Missense mutation 1.9 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E311Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.L68I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.9 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E312Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.Q95K+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.9 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E313Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119R
Missense mutation 2.1 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E315Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153A+p.D232N
Missense mutation 2.1 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E316Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143C+p.D232N
Missense mutation 2.2 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E317Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146K+p.D232N
Missense mutation 2.2 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E318Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72T+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 2.4 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E319Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.V151A+p.D232N
Missense mutation 2.7 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E320Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153F+p.D232N
Missense mutation 2.7 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E321Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143R+p.D232N
Missense mutation 3.4 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E324Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A
Missense mutation 3.8 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E325Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72A+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 4.2 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E326Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146R+p.D232N
Missense mutation 4.9 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E328Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.D232N
Missense mutation 5 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E329Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140A+p.D232N
Missense mutation 5.4 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E330Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72N+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 6.1 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E332Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146P+p.D232N
Missense mutation 6.5 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E333Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 6.5 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E334Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140C+p.D232N
Missense mutation 7.5 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E335Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148H+p.D232N
Missense mutation 8.7 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E336Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 9.3 Susceptible [7]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E337Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A128T
Missense mutation 1.5 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A128T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A91E
Missense mutation 1.1 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A91E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.H51Y+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 4 Susceptible [8]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, H51Y, I72V, S123G, T124A, K127R, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N+p.R263K
Missense mutation 4.9 Susceptible [8]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72V, S123G, T124A, K127R, D232N, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
Missense mutation 2.5 Susceptible [8]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72V, S123G, T124A, K127R, E157Q, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 9.4 Susceptible [9]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72V, S123G, T124A, K127R, S147G, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153Y+p.D232N
Missense mutation 4.4 Susceptible [8]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10D, I72V, S123G, T124A, K127R, S153Y, D232N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138A
Missense mutation 1.3 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K
Missense mutation 1.2 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E157K
Missense mutation 1.4 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E157K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E157Q
Missense mutation 1.8 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E157Q.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E170A
Missense mutation 1.6 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E170A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92G
Missense mutation 9 Susceptible [11]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G118R
Missense mutation 4.9 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G118R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140A
Missense mutation 5.4 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140C
Missense mutation 6.1 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140C.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140E
Missense mutation 2.4 Susceptible [10]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140S
Missense mutation 5 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G163K
Missense mutation 1.5 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G163K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G70R
Missense mutation 2 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G70R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.H51Y
Missense mutation 2.8 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included H51Y.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72A
Missense mutation 4.2 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72N
Missense mutation 6.1 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72T
Missense mutation 2.4 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Q148H+p.L234V
Missense mutation 6.4 Susceptible [9]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Q148H, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.S147G+p.L234V
Missense mutation 8 Susceptible [9]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, S147G, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143A+p.S230R+p.L234V
Missense mutation 9.1 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143A, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143G+p.S230R+p.L234V
Missense mutation 7.1 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143G, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.Y143S+p.S230R+p.L234V
Missense mutation 5.9 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, Y143S, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143A+p.L234V
Missense mutation 9.8 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143A, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143G+p.L234V
Missense mutation 8.8 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143G, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74I+p.T97A+p.I113V+p.Y143H+p.S230R+p.L234V
Missense mutation 7 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74I, T97A, I113V, Y143H, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143A+p.L234V
Missense mutation 8 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143A, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143G+p.L234V
Missense mutation 6.8 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143G, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.L74M+p.T97A+p.I113V+p.Y143H+p.S230R+p.L234V
Missense mutation 9 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, L74M, T97A, I113V, Y143H, S230R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143A+p.L234V
Missense mutation 7.1 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143A, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143G+p.G163R+p.L234V
Missense mutation 9.8 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143G, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143R+p.L234V
Missense mutation 8 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.T97A+p.I113V+p.Y143S+p.G163R+p.L234V
Missense mutation 5.2 Susceptible [13]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, T97A, I113V, Y143S, G163R, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L234F
Missense mutation 1.3 Susceptible [10]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L234F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L68I
Missense mutation 1.9 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L68I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L68V
Missense mutation 1.7 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L68V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74I+p.T97A
Missense mutation 3.7 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74I, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74I
Missense mutation 1.7 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.S119P
Missense mutation 2.4 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.S119R
Missense mutation 4 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119G
Missense mutation 8.9 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119T
Missense mutation 7.8 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A
Missense mutation 4.9 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M
Missense mutation 2.3 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I+p.T97A
Missense mutation 3.5 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50I, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.NULL
Missense mutation 1.8 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included NULL.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q146K
Missense mutation 2.2 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q146P
Missense mutation 6.5 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q146R
Missense mutation 4.9 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148H
Missense mutation 4.9 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q95K
Missense mutation 1.9 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q95K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q95R
Missense mutation 1.7 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q95R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R263K
Missense mutation 4.6 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153A
Missense mutation 1.9 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153F
Missense mutation 2.7 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153Y+p.L234F
Missense mutation 3 Susceptible [10]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y, L234F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153Y
Missense mutation 3 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T122I
Missense mutation 1.7 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T122I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66A
Missense mutation 7.6 Susceptible [11]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I
Missense mutation 9.7 Susceptible [11]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.G118R+p.S119R
Missense mutation 4.1 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G118R, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.G118R
Missense mutation 8.6 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G118R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.G163R
Missense mutation 2.9 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G163R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119G
Missense mutation 5.8 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119P
Missense mutation 9.5 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119T
Missense mutation 5.2 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97I
Missense mutation 1.8 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97S
Missense mutation 2 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97V
Missense mutation 2.8 Susceptible [14]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V151A
Missense mutation 2.7 Susceptible [15]
Sensitive Drug Elvitegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V151A.
References
Ref 1 Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother. 2015 Feb;70(2):405-11. doi: 10.1093/jac/dku387. Epub 2014 Oct 3.
Ref 2 The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. AIDS. 2015 Jul 31;29(12):1459-66. doi: 10.1097/QAD.0000000000000752.
Ref 3 Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility. AIDS Res Hum Retroviruses. 2016 Jul;32(7):702-4. doi: 10.1089/AID.2016.0038. Epub 2016 Apr 19.
Ref 4 Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyLancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3. Epub 2011 Oct 18.
Ref 5 Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialLancet. 2012 Jun 30;379(9835):2429-2438. doi: 10.1016/S0140-6736(12)60918-0.
Ref 6 Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksLancet. 2012 Jun 30;379(9835):2439-2448. doi: 10.1016/S0140-6736(12)60917-9.
Ref 7 Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-na ve individuals. J Med Virol. 2019 Dec;91(12):2188-2194. doi: 10.1002/jmv.25564. Epub 2019 Aug 20.
Ref 8 Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). .
Ref 9 Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapyAntiviral Res. 2010 Jan;85(1):101-18. doi: 10.1016/j.antiviral.2009.11.004. Epub 2009 Nov 17.
Ref 10 Integrase Inhibitor Resistance Selections Initiated with Drug Resistant HIV-1.
Ref 11 Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitnessAntimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.
Ref 12 Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressureRetrovirology. 2013 Feb 22;10:22. doi: 10.1186/1742-4690-10-22.
Ref 13 Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravirAntimicrob Agents Chemother. 2013 Sep;57(9):4105-13. doi: 10.1128/AAC.00204-13. Epub 2013 Jun 3.
Ref 14 Bictegravir Resistance Profile: Data for External Experts.
Ref 15 Pre-existing HIV-1 integrase polymorphisms do not impact treatment response to elvitegravir-containing fixed-dose combination regimens in treatment-naive patients.
Ref 16 Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.